Bellicum Pharmaceuticals Competitors and Similar CompaniesClear all
Bellicum Pharmaceuticals's competitors and similar companies include Celyad, Bluebird Bio, Allogene Therapeutics and Adaptimmune.
 Bellicum Pharmaceuticals Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. |  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. |  Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. | ||
Founding Date | Founding Date 2004 | Founding Date 2007 | Founding Date 1992 | Founding Date 2018 | Founding Date 2008 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Houston, US HQ Houston, US Houston, US South San Francisco, US | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations Somerville, US HQ | Locations South San Francisco, US HQ | Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB |
Employees | Employees 1386% increase | Employees 17 | Employees 32338% decrease | Employees 35917% increase | Employees 4007% decrease |
Valuation ($) | Valuation ($) 778.3 k | Valuation ($) 11.8 m | Valuation ($) 95.4 m | Valuation ($) 585.5 m | Valuation ($) 188.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $1.5m (FY, 2022) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $83.8m (FY, 2024) | Revenue (est.) $22k (FY, 2024) | Revenue (est.) $178m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods €69k (FY, 2023) | Cost of goods $89.4m (FY, 2024) | Cost of goods N/A | Cost of goods $70k (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit €1.4m (FY, 2023) | Gross profit ($5.6m) (FY, 2024) | Gross profit N/A | Gross profit $178m (FY, 2024) |
Net income | Net income ($25m) (FY, 2022) | Net income (€8.4m) (FY, 2023) | Net income ($240.7m) (FY, 2024) | Net income ($257.6m) (FY, 2024) | Net income ($70.8m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 409m | Total funding raised $ 532m | Total funding raised $ 107.5m |
For sources of this data, please see the company profile
View Company Profiles
Celyad
HQ
Mont-Saint-Guibert, BE
Employees
17
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View company
Bluebird Bio
HQ
Somerville, US
Employees
323↓ 38% decrease
Bluebird Bio is a developer of gene therapies for severe genetic diseases.
View companyAllogene Therapeutics
HQ
South San Francisco, US
Employees
359↑ 17% increase
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
View companyAdaptimmune
HQ
Philadelphia, US
Employees
400↓ 7% decrease
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
View company